Kingstone Capital Partners Texas LLC Buys New Shares in Sensus Healthcare, Inc. $SRTS

Key Points

• Kingstone Capital Partners Texas LLC has acquired a new position in Sensus Healthcare, purchasing 668,880 shares valued at approximately $3.17 million, representing 4.07% of the company as of its latest filing.
• Sensus Healthcare reported a quarterly loss of ($0.06) earnings per share, missing analysts' consensus estimates, and had revenue of $7.32 million, below expectations of $9.30 million.
• Analysts have mixed opinions on Sensus Healthcare, with price targets being lowered by HC Wainwright and Lake Street Capital, while three analysts still rate the stock as a "Buy", with an average price target of $8.00.

Kingstone Capital Partners Texas LLC bought a new stake in Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 668,880 shares of the company's stock, valued at approximately $3,170,000. Kingstone Capital Partners Texas LLC owned 4.07% of Sensus Healthcare as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the business. Northern Trust Corp raised its stake in Sensus Healthcare by 67.3% during the fourth quarter. Northern Trust Corp now owns 88,720 shares of the company's stock worth $614,000 after acquiring an additional 35,676 shares in the last quarter. Jane Street Group LLC raised its stake in shares of Sensus Healthcare by 233.7% in the fourth quarter. Jane Street Group LLC now owns 47,623 shares of the company's stock valued at $330,000 after buying an additional 33,353 shares during the period. BNP Paribas Financial Markets purchased a new position in Sensus Healthcare during the 4th quarter valued at about $47,000. Millennium Management LLC grew its stake in Sensus Healthcare by 256.6% in the 4th quarter. Millennium Management LLC now owns 85,329 shares of the company's stock worth $590,000 after buying an additional 61,403 shares in the last quarter. Finally, Man Group plc raised its position in Sensus Healthcare by 34.0% in the 4th quarter. Man Group plc now owns 59,338 shares of the company's stock worth $411,000 after purchasing an additional 15,059 shares during the period. Institutional investors own 25.30% of the company's stock.

Sensus Healthcare Stock Up 1.3%

NASDAQ SRTS traded up $0.04 on Monday, reaching $3.15. The stock had a trading volume of 126,123 shares, compared to its average volume of 83,758. The firm has a market capitalization of $51.79 million, a price-to-earnings ratio of -52.50 and a beta of 1.41. The stock has a fifty day moving average price of $3.90 and a two-hundred day moving average price of $4.40. Sensus Healthcare, Inc. has a 12-month low of $3.03 and a 12-month high of $9.33.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.07). The company had revenue of $7.32 million for the quarter, compared to analyst estimates of $9.30 million. Sensus Healthcare had a negative return on equity of 1.58% and a negative net margin of 2.26%. Sell-side analysts forecast that Sensus Healthcare, Inc. will post 0.32 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on SRTS. Lake Street Capital dropped their target price on shares of Sensus Healthcare from $13.00 to $6.00 and set a "buy" rating on the stock in a report on Friday, August 8th. HC Wainwright dropped their target price on Sensus Healthcare from $12.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday, August 12th. Finally, Wall Street Zen downgraded Sensus Healthcare from a "hold" rating to a "sell" rating in a research note on Sunday, June 22nd. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Sensus Healthcare has a consensus rating of "Buy" and an average price target of $8.00.

Sensus Healthcare Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.